Kura will see more combo data, while a new contender from Sumitomo emerges.
ApexOnco Front Page
Recent articles
Genmab quietly reveals pipeline discontinuations and a delay to the son of Darzalex.
What similarly acting projects are still unpartnered?
After a conference lacking the wow factor, biotech winners and losers emerge.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
